GLP1R and obesity disorder: Prevention strategies require dual approaches: high-SDI regions should prioritize GLP-1 receptor agonists (e.g., semaglutide) demonstrating 18% risk reduction in obesity-related cases, alongside minimally invasive surgical techniques that reduce complication rates by 50% (40).